Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00167609
Status:
COMPLETED
Last Update Posted:
2010-04-06
First Post:
2005-09-10
Brief Title:
Efficacy and Safety of DHEA for Myotonic Dystrophy
Sponsor:
University of Versailles
Organization:
University of Versailles
Study Overview
Official Title:
Phase 3 Study of Oral Dehydroepiandrosterone DHEA in Adults With Myotonic Dystrophy
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To test the efficacy and safety of two doses of dehydroepiandrosterone DHEA in adults with myotonic dystrophy
Detailed Description:
Myotonic dystrophy is an inherited disorder that affects 1 per 8000 adults The disease is characterize by muscular dystrophy myotonia cardiac disorders cognitive function impairment hypersomnia hair loss endocrine disorders Recent small studies suggested that DHEA treatment may improve muscle strength in adults with myotonic dystrophy Thus the current study aims at investigating the safety and efficacy of a prolonged treatment with DHEA in adults with myotonic dystrophy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PS001108 | None | None | None |